Literature DB >> 6203039

Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice.

F Mokhtarian, D E McFarlin, C S Raine.   

Abstract

The autoimmune disease of the central nervous system (CNS), experimental allergic encephalomyelitis (EAE), is induced by challenge of genetically susceptible animals with spinal cord homogenates or myelin basic protein (MBP). Chronic and relapsing forms of the disease have some similarities to human demyelinating disorders, namely, multiple sclerosis, and are of particular interest. EAE can be transferred passively with sensitized lymphoid cells into syngeneic animals but transferred EAE has been believed to have limited relevance to human disease because it is usually monophasic and manifested by minimal demyelination. We report here that a single transfer of MBP-sensitized lymph node cells or T cell, in the absence of a peripheral antigen depot, leads to both acute EAE with significant primary demyelination, and chronic relapsing disease with lesions typical of demyelination over a long period. These findings have major implications for the immunological mechanisms involved in experimental and human demyelinating diseases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203039     DOI: 10.1038/309356a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  63 in total

1.  Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis.

Authors:  M E Smith; N L Eller; H F McFarland; M K Racke; C S Raine
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin.

Authors:  Niannian Ji; Nagarjun Rao; Neal M Guentzel; Bernard P Arulanandam; Thomas G Forsthuber
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

Review 3.  Heat shock protein 70: roles in multiple sclerosis.

Authors:  María José Mansilla; Xavier Montalban; Carmen Espejo
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

4.  Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.

Authors:  S D Sharma; B Nag; X M Su; D Green; E Spack; B R Clark; S Sriram
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Structural insight into the role of myelin basic protein in multiple sclerosis.

Authors:  Cynthia Husted
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

Review 6.  Mechanisms of immune-mediated demyelinating disease of the central nervous system.

Authors:  D Baker; A N Davison
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

7.  Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action.

Authors:  A Achiron; R Gilad; R Margalit; U Gabbay; I Sarova-Pinhas; I R Cohen; E Melamed; O Lider; S Noy; I Ziv
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; H Ovadia; R Mizrachi-Koll; A Ben-Nun; O Abramsky; S Slavin
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

Authors:  Y Qin; P Duquette; Y Zhang; P Talbot; R Poole; J Antel
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis.

Authors:  B Cannella; C J Hoban; Y L Gao; R Garcia-Arenas; D Lawson; M Marchionni; D Gwynne; C S Raine
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.